Arpan Tapdiya

Arpan Tapdiya

Auto-generated profile, based on publicly available information

Arpan Tapdiya

Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC, 27606, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2026 in Biosensors and Bioelectronics
Verified
Journal Article
Open access
SSSudeep Sarma
Sudeep Sarma
JPJin-Ho Park
Jin-Ho Park
YCYoung Kwan Cho
Young Kwan Cho
ATArpan Tapdiya
Arpan Tapdiya
HWHyun-Kyung Woo
Hyun-Kyung Woo
CHCarol K. Hall
Carol K. Hall
Assays for cancer diagnosis via the analysis of tumor biomarkers on circulating extracellular vesicles (EVs) have shown great potential. Single EV imaging that can measure the abundance of protein biomarkers in EVs can help in detecting the presence, stage, and progression of disease. Antibodies are typically used to detect EV proteins. Controlling the quality of antibody-based immunoassays can, however, be challenging, as they may exhibit unintended cross-reactivity with non-target proteins or variability in binding affinity across different batches, even for monoclonal antibodies. Here, we report short peptides that are a promising alternative to antibodies for detecting protein biomarkers in EVs. We describe a pipeline that combines a Peptide Binding Design (PepBD) algorithm and molecular-level simulations to identify peptides that can recognize the extracellular domain of EpCAM (a known cancer biomarker). The peptides designed for EpCAM were labeled with a fluorescent dye and their binding to the target protein was evaluated using fluorescence ELISA. The results identified a computationally designed peptide that exhibited an affinity for the target EpCAM protein comparable to that of an antibody. Further testing involved single EV imaging to gauge the peptide's affinity towards EVs.

1 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
SSSudeep Sarma
Sudeep Sarma
YCYoung Kwan Cho
Young Kwan Cho
ATArpan Tapdiya
Arpan Tapdiya
JPJin-Ho Park
Jin-Ho Park
HLHakho Lee
Hakho Lee
CHCarol K. Hall
Carol K. Hall
Assays for cancer diagnosis via the analysis of tumor biomarkers on circulating extracellular vesicles (EVs) have shown great potential. Single EV imaging that can measure the abundance of protein biomarkers in EVs can help in detecting the presence, stage, and progression of disease. Antibodies are typically used to detect EV proteins. Controlling the quality of antibody-based immunoassays can, however, be challenging, as they may exhibit unintended cross-reactivity with non-target proteins or variability in binding affinity across different batches, even for monoclonal antibodies. Here, we report short peptides that are a promising alternative to antibodies for detecting protein biomarkers in EVs. We describe an effort that combines a Pep tide B inding D esign (PepBD) algorithm and molecular-level simulations to identify peptides that can recognize (1) the extracellular domain of EpCAM (a known cancer biomarker) and (2) the extracellular domain of tetraspanin CD81(a protein commonly expressed on the surface of EVs). The peptides designed for EpCAM and CD81 were labeled with a fluorescent dye and their binding to the target protein was evaluated using fluorescence ELISA. The results demonstrated that one of the computationally designed peptides EP-2.1 exhibited an affinity for the target EpCAM protein comparable to that of an antibody. Further testing involved single EV imaging to gauge the peptide’s affinity towards EVs. Designed peptides for both the target proteins showed similar affinity as antibodies to EVs.